Summary

Overview
Global cerebrospinal fluid management market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global cerebrospinal fluid management market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The central nervous system's homeostasis is crucially maintained by cerebrospinal fluid (CSF). The management of cerebral spinal fluid (CSF) entails the use of tools like shunts or external drainage systems to keep the CSF flowing.
Government novel product launch and research, particularly in developing economies, will continue to drive utilization of advanced cerebrospinal fluid (CSF) shunt or external drainage systems and boost the global cerebrospinal fluid management market. The respective innovative products are may be utilized in people with different age groups.
Market Dynamics: Drivers & Restraints
Growing collaborations and acquisitions
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for cerebrospinal fluid management owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.
On June 27, 2023, the Spiegelberg GmbH & Co. KG (Spiegelberg), a well-known medical device firm and manufacturer of extremely specialized devices or consumables for neurosurgery, was bought by Luciole Medical AG, a Swiss health care company with a focus on brain monitoring, from SHS Capital. After the acquisition, the businesses will merge their product lines, production capabilities, and distribution networks to maximize their strengths with the goal of emerging as a leader in the development of cutting-edge next-generation brain monitoring devices.
Additionally, on June 26, 2023, LianMedical, a manufacturer of medical devices focused on speeding up the introduction of ground-breaking medical technologies to markets in Asia, and CereVasc, Inc., a clinical-stage medical device business developing new therapies for neurological diseases, joined forces to bring CereVasc's eShunt System along with associated products to consumers and healthcare professionals in China, Taiwan, Hong Kong, and Macau.
Furthermore, the rising utilization of novel technology and different types of cerebrospinal fluid management systems for the treatment or several research purposes. Rising cerebral fluid leak and increasing research for innovative management product development will be a major factor driving the growth of the cerebrospinal fluid management market.
Complications associated with the shunts
Despite improvements in surgical procedures and antibiotic prophylaxis, infection is still the most severe side effect of shunts. As a result, antimicrobial biomaterials for shunts and EVDs have been created. Understanding the surgical, biomaterials, and microbiological components of the issues is necessary for the laboratory assessment of such devices.
Most frequently, some skin flora-associated low-virulence organisms are responsible for CSF shunt infections. In approximately 50% to 80% of the shunt infections, coagulase-negative and coagulase-positive staphylococci were shown to be the common causative agents.
Segment Analysis
The global cerebrospinal fluid management market is segmented based on product type, age group, end user and region.
Cerebrospinal Fluid (CSF) Shunt segment accounted for approximately 56% of market share
Shunts of cerebrospinal fluid are employed to treat hydrocephalus, which is brought on by increased pressure inside the brain. They are meant to be permanent fixtures. External ventricular drainage (EVD), which is utilized for sudden increases in pressure such those brought on by trauma or hemorrhage, is a more transient solution. Patients have CSF shunts implanted to drain fluid from their cysts, ventricles, and subdural deposits to organs that can absorb it, including the peritoneum or atrium.
The most frequent neurosurgical procedure carried out in the US is the insertion of CSF shunts. For existing or probable hydrocephalus/fluid space collections caused by spina bifida or intraventricular hemorrhage, shunts are most frequently implanted in young patients, and they have reduced mortality from these disorders.
On February 10, 2021, the first patient in a study of CereVasc, Inc.'s eShunt System, an investigational device aimed at treating communicating hydrocephalus (CH), which is among the most prevalent neurological conditions in the world, has been treated. CereVasc, Inc. is a clinical-stage medical equipment company creating novel, minimally invasive therapies for neurological diseases. The eShunt device, the first modern minimally invasive procedure for CH, has the potential to provide considerable advantages over the standard of care, a 50-year-old neurosurgical operation marked by frequent failure, an increased risk of infection, and high costs.
Geographical Penetration
North America accounted for around 36% of market share in 2022
Due to the rising need for cerebrospinal fluid management in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for cerebrospinal fluid management.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of products, and increase in biopharmaceutical or medical device business establishment across the region are also contributing to the growth of cerebrospinal fluid management market share of this region. The market in this area is growing as people become more aware of various novel innovative products such as cerebrospinal fluid (csf) shunt. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global cerebrospinal fluid management market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for cerebrospinal fluid management in the U.S. United States have been proactive in executing several initiatives or researches, stimulating cerebrospinal fluid management demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global cerebrospinal fluid management market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for cerebrospinal fluid management. Now several research studies have been initiated and companies have again started launching novel products with high efficiency. Overall, the impact of the pandemic on the global cerebrospinal fluid management market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for innovative products, like external drainage system.
Key Developments
• On July 6, 2023, the External Ventricular Drain (EVD) catheter set, Codman Bactiseal is used to treat patients who have hydrocephalus as a side effect of aneurysmal subarachnoid hemorrhage (aSAH), according to positive clinical and financial results stated by Integra LifeSciences Holdings Corporation, an established global medical technology company.
• On April 8, 2022, the VentrEX Complete is the ideal option for lumbar or ventricular drainage because it includes the VentrEX EVD System with a disposable stand. Its extensive range of intelligent functions, properly labeled parts, and easy-to-read scale ensure simple handling with the highest level of safety.
Competitive Landscape
The major global players in the market include Medtronic, Integra LifeSciences, DePuy Synthes (Johnson & Johnson MedTech), B. Braun SE, Natus Medical Incorporated, Spiegelberg GmbH & Co. KG, Neuromedex GmbH, MÖLLER Medical GmbH, Argi Grup and Wellong Instruments Co., Ltd.
Why Purchase the Report?
• To visualize the global cerebrospinal fluid management market segmentation based on product type, age group, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cerebrospinal fluid management market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global cerebrospinal fluid management market report would provide approximately 61 tables, 56 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Age Group
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing collaborations and acquisitions
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Complications associated with the shunts
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Cerebrospinal Fluid (CSF) Shunt*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Ventriculoperitoneal (VP) Shunt
7.2.4. Ventriculopleural (VPL) Shunt
7.2.5. Ventriculoatrial (VA) Shunt
7.3. External Drainage System
7.3.1. External Ventricular Drainage (EVD)
7.3.2. Lumbar Drainage
7.3.3. Cisternal Drainage
8. By Age Group
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
8.1.2. Market Attractiveness Index, By Age Group
8.2. Pediatric *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adult
8.4. Geriatric
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Geriatric
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Medtronic*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Integra LifeSciences
12.3. DePuy Synthes (Johnson & Johnson MedTech)
12.4. B. Braun SE
12.5. Natus Medical Incorporated
12.6. Spiegelberg GmbH & Co. KG
12.7. Neuromedex GmbH
12.8. MÖLLER Medical GmbH
12.9. Argi Grup
12.10. Wellong Instruments Co., Ltd.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us